You are here

Amgen discounts cholesterol drug, but payers want more

Amgen executives say results of the new Repatha trial will clear the way for more patients to get access to the drug.

New York

AMGEN Inc sells its cholesterol-lowering drug Repatha at a discount of about 30 per cent to its US list price of US$14,000 a year, but the largest pharmacy benefit managers say they want lower prices after new data suggested more patients should be treated with the drug.


Market voices on: